SCHEMBL4398415

SCHEMBL4398415

Fc1cccc(-c2ncccn2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.52
DYRK1A Q13627 1/20 0.52
HPGDS O60760 4/20 0.51
GRM5 P41594 1/20 0.50
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
CDC7 O00311 1/20 0.49
ROCK2 O75116 1/20 0.49
MAP4K4 O95819 1/20 0.49
PIM1 P11309 1/20 0.49
PRKACA P17612 1/20 0.49
CDK2 P24941 1/20 0.49
GSK3B P49841 1/20 0.49
HIPK2 Q9H2X6 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
IDO1 P14902 1/20 0.48
NISCH Q9Y2I1 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
ESR2 Q92731 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14961829 0.83 CLK4 (0.61) CLK4DYRK1AMAP4K4CYP2A6
SCHEMBL28429062 0.83 HPGDS (0.49) CLK4HPGDSMAP4K4IDO1TAAR1
SCHEMBL27095783 0.81 TAAR1 (0.56) HPGDSIDO1NISCHTAAR1ESR2
SCHEMBL16719539 0.81 HPGDS (0.47) HPGDSGRM5MAP4K4IDO1NISCH
SCHEMBL10091170 0.79 HPGDS (0.54) HPGDSACHEPIM1IDO1
SCHEMBL31722154 0.79 TAAR1 (0.55) HPGDSMAP4K4IDO1TAAR1TP53
SCHEMBL25649075 0.79 NPC1 (0.46) GRM5BCHEACHETP53KMO
SCHEMBL16719958 0.79 HPGDS (0.40) CLK4HPGDSGRM5BCHEACHE
SCHEMBL27854208 0.79 KMO (0.44) HPGDSGRM5BCHEACHEIDO1
SCHEMBL29637608 0.78 CLK4 (0.57) CLK4DYRK1ACYP3A4CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105461699-B Substituted heterocyclic compound and its application method and purposes 广东东阳光药业有限公司 2019-07-09 CN disclosed
CN-101646656-B Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI AVENTIS SPA 2013-08-14 CN disclosed
CN-101646656-A Pyrimidine hydrazide compounds as the PGDS inhibitor SANOFI AVENTIS FR 2010-02-10 CN disclosed
US-20090306038-A1 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity PALAU PHARMA, S.A. (ES) 2009-12-10 US disclosed
WO-1997020827-A1 FLUOROPHENYL-TRIAZINE AND PYRIMIDINE DERIVATIVES AS COMPOUNDS ACTING ON THE CENTRAL NERVOUS SYSTEM LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 1997-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306038-A1 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity HRH4, HRH2, HRH3 CLK4 4558/4885DYRK1A 3466/4885HPGDS 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.